20:53 , Oct 5, 2017 |  BC Innovations  |  Translation in Brief

AMPK addendum

A Science paper form Merck & Co. Inc. (NYSE:MRK) suggests that while AMP-activated protein kinase (AMPK) agonists can reduce blood sugar levels and treat diabetes models, they also cause cardiac defects, casting doubt on AMPK...
20:00 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest AMPK activators could help treat non-alcoholic fatty liver disease (NAFLD). In mice, liver-specific expression of an overactive human mutant AMPK decreased glucose production and fatty acid synthesis compared with no...
19:00 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Myotonic dystrophy type 1 (DM1) Patient sample and mouse studies suggest activating AMPK or inhibiting mTORC1 could help treat DM1. In muscle tissue samples from patients and a genetic mouse model of DM1, levels of...
18:15 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes In vitro, cell culture and mouse studies identified a pyrrolidine-based FFAR1 agonist that could help treat Type II diabetes. Chemical synthesis and testing in cell-based assays of pyrrolidine analogs identified a compound that agonized...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ghrelin; acyl-ghrelin; AMP-activated protein kinase (AMPK)

Neurology INDICATION: Parkinson's disease (PD) Mouse and cell culture studies suggest activating the ghrelin-AMPK pathway could help treat PD. In a mouse model of PD, caloric restriction, which elevates plasma level of ghrelin, decreased the loss of...
08:00 , Feb 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Bone repair; osteoporosis Free fatty acid receptor 1 (FFAR1; GPR40) Studies...
08:00 , Jan 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) In vitro and mouse studies identified an alkyne...
07:00 , Aug 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Free fatty acid receptor 1 (FFAR1; GPR40) Mouse and in vitro studies have identified GPR40...
07:00 , Apr 30, 2012 |  BioCentury  |  Product Development

Beyond statins: LDL diversity

No fewer than 20 companies are working on next-generation lipid-lowering agents intended to improve upon the benefits of statins, which lower LDL-C and reduce the risk of cardiovascular events but still leave millions of people...
08:00 , Feb 16, 2012 |  BC Innovations  |  Targets & Mechanisms

Still un-sirtuin

Researchers at the NIH have proposed a new mechanism to explain the beneficial metabolic effects of resveratrol, a polyphenol compound from red wine thought by many to act primarily on sirtuin 1. The NIH team...